Acelyrin (NASDAQ:SLRN) announced Thursday a decision to adopt a limited-duration stockholder rights plan, also known as a poison pill, after Tang Capital Partners rapidly accumulated 8.8% of the ...

While Pliant Therapeutics and Acelyrin recently blocked ever-eager acquirer Concentra Biosciences with “poison pill” defenses, struggling Allakos is welcoming a $0.33 per share buyout offer wi ...

also known as a poison pill, on March 13. The rights plan is effective immediately and will expire on March 12 of next year. The unsolicited offer, received on Feb. 20, sent Acelyrin’s share ...

Alis Biosciences’ plan is a familiar tactic in the private equity world, but the firm will instead be listed on the public ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter.

Alumis (ALMS) and Acelyrin (SLRN) announced an amendment to the existing terms of their previously announced merger agreement: Acelyrin ...

A potential buyer threatened to upend Alumis Inc.'s merger deal with Acelyrin Inc. as late as Monday, according to a Securities and Exchange Commission filings Thursday detailing the merger.

Acelyrin said Tang Capital held 8.8% of its outstanding common stock. Tang Capital didn't immediately respond to a request for comment issued through LinkedIn. Poison pills, also called ...